Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Mol Cancer Res. 2013 Sep 18;11(12):10.1158/1541-7786.MCR-13-0187. doi: 10.1158/1541-7786.MCR-13-0187

Figure 3.

Figure 3

IL6 signaling affects response to erlotinib in head and neck (HNSCC) cells. FaDu cells were pre-treated with 100 ng/mL of human recombinant IL-6 for 2 h before treatment with or without 5 μM erlotinib (ERL) for 48 h. Treated cells were analyzed for cytotoxicity via clonogenic analysis (A). DMSO was used as a control (CON). FaDu cells were treated with 1 μM of the IL-6 receptor antagonist tocilizumab (TOC) or IgG with or without 5 μM erlotinib (ERL) for 48 hours then analyzed by clonogenic assay (B). Athymic (nu/nu) mice bearing FaDu (C) and SQ20B (D) xenograft tumors were treated with 1 mg/mouse tocilizumab (TOC) and/or 12 mg/kg erlotinib (ERL) for 10 days. Tocilizumab was given i.p. every other day and erlotinib was given by oral gavage every day. Control mice (CON) received IgG. Data points represent the average values for 9 mice. Error bars represent the standard error of the mean (SEM). *:p<0.05 versus DMSO or IgG control. **:p<0.05 versus ERL.